As SCD1 and DGAT2 enzymes are potential targets for the treatment of NAFLD and clinical trials are ongoing, PHF2 and KDM7A could provide potential therapeutic targets in treating NAFLD. This evidence concerns the gene DGAT2 and metabolic dysfunction-associated steatotic liver disease.